Key Takeaways from Exact Sciences Stock's Earnings

Short interest is an important metric that could determine, at least in the near term, the general direction of a company's share price. Exact Sciences  (NASDAQ: EXAS  )  has been one of the most heavily shorted stocks in the health-care sector this year, despite making significant progress on the clinical and regulatory fronts for its noninvasive "Cologuard" colorectal cancer screening test. Even so, the company's share price has ballooned upward by over 40% to date in 2014.

Exact's strong performance in the face of high short interest is directly tied to Cologuard's march toward approval. Specifically, an advisory committee for the Food and Drug Administration voted unanimously in March in support of the product's approval.

With peak sales estimated at between $1 billion and $2 billion annually for this novel molecular diagnostic, shorts would appear to have ample reasons to hit the exits prior to final approval and commercialization. The latest short numbers demonstrate a small dip in short interest in recent weeks, as shown by the chart below. With this in mind, let's look at the key takeaways from Exact's second-quarter earnings release yesterday and consider whether shorts should continue their exodus. 

EXAS Chart

EXAS data by YCharts.

Exact Sciences is gearing up for Cologuard's launch
Although Exact's second-quarter numbers aren't pretty from a fundamental perspective, they tell the story of a company on the cusp of morphing into a commercial operation. For the quarter, the company's net loss per share grew to $0.24 from $0.19 for the same period a year ago. Management noted on the earnings conference call that a big chunk of this increase was due to the hiring of a 120-member sales team that averages over 10 years of experience in the field.

As a result, Exact's run-rate rose to approximately $6.5 million per month for the quarter, compared to roughly $3.8 million a year ago. Going forward, the company expects its sales force to grow up to 150 by year-end and the run rate to potentially exceed $7.5 million a month. With $234.8 million remaining in cash and cash equivalents, the company should have a cash runway of two-plus years, excluding revenue from Cologuard. Put simply, Exact should have more than enough cash to successfully launch this product, assuming final approval is forthcoming.

Regulatory and payer updates
Management also noted on the call the final FDA approval looks to be about 30 to 45 days away. The FDA inspection wrapped up without finding deficiencies in Cologuard. As a result, the last major hurdle appears to be the details of the required post-marketing studies.  

On the call, we also learned that Exact has formally discussed a proposed reimbursement scheme for Cologuard with the Centers for Medicare & Medicaid Services, with the proposed total price coming in at $502. Management expects a decision from CMS in the fourth quarter of this year, but private payers won't make their decision until after final FDA approval. 

The major effect of these payer issues will be that revenue from Cologuard, assuming approval, will probably be minimal this year. Essentially, the vast majority of the initial group of patients will have to pay out of pocket. With reimbursement issues seemingly set to be resolved late this year, we should get a better feel for Cologuard's real commercial potential in the first quarter of 2015. 

Foolish wrap-up
Based on what we know now, investors and shorts alike should be asking themselves if Exact looks like a long-term winner. My view is that Exact will probably do fairly well with Cologuard in the near term, but its long-term prospects are less favorable.

The main problem is that Exact will be highly dependent upon Cologuard for top-line growth and the diagnostic field is known for its extreme level of competition. If Cologuard begins to take off, I would imagine diagnostic makers such as Meridian Biosciences and Thermo Fisher Scientific will get in on the act. Indeed, these two companies are already battling over a number of diagnostic tests, especially in the C. difficile product arena. 

Perhaps seeing the writing on the proverbial wall, Exact's management noted that it is actively developing additional GI diagnostic tools based on this same technology. That being said, I don't believe Cologuard will end up garnering the lofty sales numbers projected initially, because this area is simply too prone to attracting copycats, many of which have far more resources than Exact.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 27, 2014, at 2:56 PM, Mikey925 wrote:

    With all due respect, I totally disagree with the author's conclusion that other molecular diagnostic companies (Thermo Fischer Scientific or Meridian Bioscience) will be able to jump into this space.

    The fact of the matter is that EXAS has built a massive IP "moat" around their Company. For example, they own patents in the area of the extraction of DNA from stool.

    Moreover, the entire lab process has been automated. Many of the molecular diagnostic machines in the lab process have been "roboticized" in a proprietary fashion and software had to be written. With all of this automation, the process still takes 8 hours from start to finish.

    Think that another diagnostic company would try to "copy-cat" Exact's lab but go the "manual" route and take up to 45 hours to process one sample? Think again.

    Any other Company that would try and "jump-in" to this space is facing massive technology hurdles and roadblocks. The automation process that Exact has been able to develop over the last 4 years is nothing short of monumental. It could not be bought from "third-parties" and installed in a cookie-cutter fashion. It was built from the ground up by Graham Lidgard, an incredible innovator in the molecular diagnostics space.

    Even if someone were to assume that another Company were to be committed enough to get involved in non-invasive colon cancer screening using DNA methylation markers, they are already 5 years behind.

    I think that EXAS has a 10-15 year runway with ColoGuard. And when they start adding other molecular tests into the ColoGuard assay (such as Pancreatic and Esophageal) the gross margins will surge even further.

    And should the US Preventative Services Task Force wind up lowering the recommended age for colon cancer screening to 40, the addressable market for ColoGuard would increase by 50%, from 80 million to 120 million. Being able to add a non-invasive Pancreatic Cancer test into the stool DNA technology platform that Exact controls, would ultimately push an advisory panel such as USPSTF towards a lower age for screening.

    In any event, anyone that thinks that it would be "easy" for another diagnostic company to enter this space is being incredibly naïve. It's not profitable unless you automate the process. And it's highly unlikely that Exact will be "licensing" any part of their lab process to anyone . . . even if it was for "other" diagnostic tests that have nothing to do with ColoGuard.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3039942, ~/Articles/ArticleHandler.aspx, 12/20/2014 5:31:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement